Abstract
Over the last two decades, four major therapeutic approaches have dramatically changed the prognosis in chronic myelogenous leukemia(CML). Those include allogeneic stem cell transplantation, interferon-alpha based regimen, donor-leukocyte infusions, and the revolutionary BCR/ABL tyrosine kinase inhibitor such as STI571. Each modality has exploited and targeted different aspects of CML biology, and is associated with different risk-benefit ratios. In this section, we update the results of both related and unrelated donor transplantation, donor lymphocyte infusions, and non-myeloablative stem cell transplantation in CML in comparison with the other treatment modalities.
| Original language | English |
|---|---|
| Pages (from-to) | 2375-2382 |
| Number of pages | 8 |
| Journal | Nippon rinsho. Japanese journal of clinical medicine |
| Volume | 59 |
| Issue number | 12 |
| Publication status | Published - 2001 Dec |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Allogeneic stem cell transplantation. / Sawafuji, K.; Okamoto, Shinichiro.
In: Nippon rinsho. Japanese journal of clinical medicine, Vol. 59, No. 12, 12.2001, p. 2375-2382.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Allogeneic stem cell transplantation
AU - Sawafuji, K.
AU - Okamoto, Shinichiro
PY - 2001/12
Y1 - 2001/12
N2 - Over the last two decades, four major therapeutic approaches have dramatically changed the prognosis in chronic myelogenous leukemia(CML). Those include allogeneic stem cell transplantation, interferon-alpha based regimen, donor-leukocyte infusions, and the revolutionary BCR/ABL tyrosine kinase inhibitor such as STI571. Each modality has exploited and targeted different aspects of CML biology, and is associated with different risk-benefit ratios. In this section, we update the results of both related and unrelated donor transplantation, donor lymphocyte infusions, and non-myeloablative stem cell transplantation in CML in comparison with the other treatment modalities.
AB - Over the last two decades, four major therapeutic approaches have dramatically changed the prognosis in chronic myelogenous leukemia(CML). Those include allogeneic stem cell transplantation, interferon-alpha based regimen, donor-leukocyte infusions, and the revolutionary BCR/ABL tyrosine kinase inhibitor such as STI571. Each modality has exploited and targeted different aspects of CML biology, and is associated with different risk-benefit ratios. In this section, we update the results of both related and unrelated donor transplantation, donor lymphocyte infusions, and non-myeloablative stem cell transplantation in CML in comparison with the other treatment modalities.
UR - http://www.scopus.com/inward/record.url?scp=0035650847&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035650847&partnerID=8YFLogxK
M3 - Article
C2 - 11766342
AN - SCOPUS:0035650847
VL - 59
SP - 2375
EP - 2382
JO - Nihon rinsho. Japanese journal of clinical medicine
JF - Nihon rinsho. Japanese journal of clinical medicine
SN - 0047-1852
IS - 12
ER -